PharmaResearch Co., Ltd.

KOSDAQ:A214450 Stock Report

Market Cap: ₩2.6t

PharmaResearch Past Earnings Performance

Past criteria checks 5/6

PharmaResearch has been growing earnings at an average annual rate of 28.6%, while the Biotechs industry saw earnings growing at 2.7% annually. Revenues have been growing at an average rate of 27.2% per year. PharmaResearch's return on equity is 16.2%, and it has net margins of 28%.

Key information

28.6%

Earnings growth rate

27.1%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate27.2%
Return on equity16.2%
Net Margin28.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

What PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 32% Share Price Gain Is Not Telling You

Dec 19
What PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 32% Share Price Gain Is Not Telling You

PharmaResearch Co., Ltd. (KOSDAQ:214450) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Aug 15
PharmaResearch Co., Ltd. (KOSDAQ:214450) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Here's Why We Think PharmaResearch (KOSDAQ:214450) Might Deserve Your Attention Today

May 21
Here's Why We Think PharmaResearch (KOSDAQ:214450) Might Deserve Your Attention Today

PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up

Apr 09
PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up

Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?

Mar 23
Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?

Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?

Mar 05
Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?

Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?

Feb 17
Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?

Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year

Feb 02
Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year

Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?

Jan 20
Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?

Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like

Jan 07
Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like

Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?

Dec 23
Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?

Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?

Dec 08
Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?

Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?

Nov 25
Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?

Revenue & Expenses Breakdown

How PharmaResearch makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A214450 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24316,99788,75783,40919,946
30 Jun 24296,59490,74479,23617,727
31 Mar 24280,28576,09278,48716,189
31 Dec 23261,01176,55174,41115,030
30 Sep 23244,66164,90270,84912,506
30 Jun 23222,03055,61566,21711,481
31 Mar 23204,93248,96460,5129,706
31 Dec 22194,75940,57758,8638,702
30 Sep 22183,19146,50153,4878,305
30 Jun 22175,71942,36650,7407,578
31 Mar 22164,81343,75246,5567,002
31 Dec 21154,08346,68942,4486,738
30 Sep 21143,28247,11036,4926,581
30 Jun 21133,70641,53433,4936,792
31 Mar 21122,60940,15330,8436,167
31 Dec 20108,74632,77428,2955,543
30 Sep 20101,28227,00326,6475,673
30 Jun 2091,74723,10924,3565,386
31 Mar 2084,09116,40721,8915,569
31 Dec 1983,87216,66720,9555,614
30 Sep 1977,41619,06021,2824,823
30 Jun 1973,32416,38421,7134,367
31 Mar 1970,24215,31022,6364,176
31 Dec 1864,28114,40821,0224,043
30 Sep 1861,8656,91323,2214,379
30 Jun 1860,77711,13420,3454,529
31 Mar 1856,51912,57917,1745,206
31 Dec 1754,47012,95616,0154,497
30 Sep 1750,61514,52211,2735,149
30 Jun 1747,24113,47210,7824,269
31 Mar 1746,58014,37811,2133,447
31 Dec 1645,95313,90912,7623,378
30 Sep 1645,09216,72511,3022,309
31 Dec 1537,45512,8787,3541,763

Quality Earnings: A214450 has high quality earnings.

Growing Profit Margin: A214450's current net profit margins (28%) are higher than last year (26.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A214450's earnings have grown significantly by 28.6% per year over the past 5 years.

Accelerating Growth: A214450's earnings growth over the past year (36.8%) exceeds its 5-year average (28.6% per year).

Earnings vs Industry: A214450 earnings growth over the past year (36.8%) exceeded the Biotechs industry 7.9%.

Return on Equity

High ROE: A214450's Return on Equity (16.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 00:26
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PharmaResearch Co., Ltd. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sae-rom LeeDaishin Securities Co. Ltd.
Jonghyun ParkDAOL Investment & Securities Co., Ltd.
Tae-Na JoEugene Investment & Securities Co Ltd.